CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00707863
NCT00707863Phase 4Completed
CompareCT.gov

fMRI and Genotype Markers of Antidepressant Side Effects and Response in Young Adults Compare to Older Adults

Indiana University·interventional·Posted Jul 1, 2008·Updated Oct 17, 2016

In Brief

A Phase 4 clinical trial evaluating Escitalopram for Major Depression. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 1, 2008
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.0 years ago

Interventions

Escitalopramdrug

10 mg of Escitalopram by mouth once a day for 8 weeks